ENCLAI Daily · Article of the day 07 Oct 2026 · ENCLAI Editorial

Long-acting HIV injections show no viral rebound in suppressed teens at 96 weeks

NEW MEDICAL STUDY EXPLAINED · 07 OCTOBER 2026Long-acting HIV injections show no viralrebound in suppressed teens at 96 weeksPubMed 42838065Early-phase /non-randomised trial ·Study typeLancet Child & adolescenthealthjournal6 Oct 2026publishedIn a phase 1/2 trial of 144 virologically suppressed adolescents,long-acting cabotegravir plus rilpivirine injections resulted inzero confirmed virological failures through week 96.What the study found1Between July 26, 2021, and August 27, 2022, 144 participants enrolledin the trial, with a median age of 15 years.2Through week 96, there were no confirmed virological failures amongthe participants.3Median week 96 observed trough concentrations of cabotegravir were2.96 μg/mL and rilpivirine were 89.5 ng/mL, approximating levels seenin adults.Who it applies toThe trial enrolled adolescents aged 12to 17 years who weighed at least 35 kgand were living with HIV-1.Participants were required to bevirologically suppressed at the timeof enrollment.What it does not establishThe study was a single-arm,non-comparative trial, meaning resultswere not compared against a controlgroup. Through week 96, 35 of 144participants (24%) had an adverseevent of grade 3 or higher, with a 95%CI of 17.6 to 32.2.The authors' conclusion“96-week study data show sustained safety and antiviral activity,favourable pharmacokinetics, and good acceptability and tolerability inadolescents living with HIV who were virologically suppressed, informthe growing global approvals, and support the ongoing clinical use ofinjectable cabotegravir plus rilpivirine in this age group.”Summary of the published abstract, not medical advice. Read the paper before acting on it.Source: PubMed 42838065 · enclai.net/newsVerify every figure against the source before use; ENCLAI does not guarantee accuracy orcompleteness.
  1. In a phase 1/2 trial of 144 virologically suppressed adolescents, long-acting cabotegravir plus rilpivirine injections resulted in zero confirmed virological failures through week 96.
  2. Between July 26, 2021, and August 27, 2022, 144 participants enrolled in the trial, with a median age of 15 years.
  3. Through week 96, there were no confirmed virological failures among the participants.
  4. Median week 96 observed trough concentrations of cabotegravir were 2.96 μg/mL and rilpivirine were 89.5 ng/mL, approximating levels seen in adults.
Customise it in Visual Studio
Infographic — study at a glance
What the authors report
Evidence and source
Infographic — study at a glance

The publication

In a phase 1/2 trial of 144 virologically suppressed adolescents, long-acting cabotegravir plus rilpivirine injections resulted in zero confirmed virological failures through week 96. The study also reported that 24% of participants experienced grade 3 or higher adverse events, with no grade 3 or higher drug-related adverse events occurring after week 96.

Who the findings apply to

The trial enrolled adolescents aged 12 to 17 years who weighed at least 35 kg and were living with HIV-1.

Participants were required to be virologically suppressed at the time of enrollment.

The study was conducted across 18 sites in Botswana, South Africa, Thailand, Uganda, and the USA.

Why this matters

The findings demonstrate that the adult dosing regimen of long-acting cabotegravir plus rilpivirine maintains viral suppression and acceptable safety in adolescents aged 12 to 17 years. This supports the ongoing clinical use of injectable therapy in this age group and informs global approvals for long-acting HIV treatment options.

What the study found

Between July 26, 2021, and August 27, 2022, 144 participants enrolled in the trial, with a median age of 15 years.

Through week 96, there were no confirmed virological failures among the participants.

Median week 96 observed trough concentrations of cabotegravir were 2.96 μg/mL and rilpivirine were 89.5 ng/mL, approximating levels seen in adults.

At least 97% of participants on treatment preferred injectable treatment to daily oral treatment through week 96.

What the result does not establish

The study was a single-arm, non-comparative trial, meaning results were not compared against a control group.

Through week 96, 35 of 144 participants (24%) had an adverse event of grade 3 or higher, with a 95% CI of 17.6 to 32.2.

Three participants had a drug-related adverse event of grade 3 or higher, representing 2% of the cohort with a 95% CI of 0.4 to 6.0.

The trial was not designed to compare efficacy against other antiretroviral regimens, only to evaluate safety and activity of the specific injectable combination.

Authors’ conclusion

“96-week study data show sustained safety and antiviral activity, favourable pharmacokinetics, and good acceptability and tolerability in adolescents living with HIV who were virologically suppressed, inform the growing global approvals, and support the ongoing clinical use of injectable cabotegravir plus rilpivirine in this age group.”

Trial registration

NCT03497676

Registered titleMore Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (MOCHA)
Registry statusPhase 1 / Phase 2, interventional, completed
Lead sponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Registered size168 participants — actual enrolment
Where19 sites in 5 countries (Botswana, South Africa, Thailand, Uganda, United States)
Registered primary outcomes
  • Proportion of Participants Who Had Grade 3 or Higher Adverse Event (Cohort 1) (time frame: Cohort 1 Treatment Initiation through Week 4)
  • Proportion of Participants Who Had Grade 3 or Higher Adverse Events Assessed as Related to Study Product/s (Cohort 1) (time frame: Cohort 1 Treatment Initiation through Week 4)
  • Proportion of Participants Who Had Serious Adverse Events Meeting International Conference on Harmonisation (ICH) Criteria Assessed as Related to Study Product/s (Cohort 1) (time frame: Cohort 1 Treatment Initiation through Week 4)
  • and 25 more
Results on the registryPosted May 2024
  • Start: Apr 2019
  • Primary completion: Feb 2023
  • Results posted: May 2024
  • Completion: Apr 2025
  • Paper published: Oct 2026
Filled circle: date reached. Open circle: date the registry lists as estimated.

ClinicalTrials.gov record as held by ENCLAI, last updated Jan 2026. The registry status may have changed since; the link shows the current record.

Study and sources

Safety, antiviral activity, and pharmacokinetics of long-acting cabotegravir plus long-acting rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): week 96 and end-of-study results from a multinational, phase 1/2, single-arm trial

Early-phase / non-randomised trial · Phase 1/2 · Lancet Child & adolescent health · 2026-10-06

Sources and limitations

Share this briefing
ENCLAI tracks outbreaks like this live, from official sources worldwide. Start 7-day free trial  ·  Request a demo →

Follow ENCLAI News

Get new briefings in your news reader. No ENCLAI account needed.

The daily disease brief

One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.

Double opt-in — we send a confirmation link and nothing else until you click it. One-click unsubscribe on every email. See our privacy notice.